Quick Summary
- Trial Success: Phase 3 LIBRETTO-432 trial met primary endpoint, showing Retevmo reduced disease recurrence/death risk in early-stage RET fusion-positive NSCLC patients.
- Patient Population: Targets rare subset (1-2% of NSCLC cases) with RET fusions in stage II-IIIA disease.
- Trial Design: 151 patients randomized 1:1 to receive Retevmo or placebo after surgery/radiation and adjuvant therapy.
- Key Results: Statistically significant improvement in event-free survival; overall survival data trending favorably but still immature.
- Next Steps: Results to be presented at medical congress, submitted for peer review, and discussed with health authorities for potential label expansion
Eli Lilly and Company announced positive topline results from its Phase 3 LIBRETTO-432 clinical trial, revealing that Retevmo (selpercatinib) demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death when used as an adjuvant therapy in patients with early-stage RET fusion-positive non-small cell lung cancer (NSCLC).
The trial met its primary endpoint of investigator-assessed event-free survival (EFS) in patients with stage II-IIIA disease, marking a significant advancement in the treatment landscape for this molecularly defined patient population. Overall survival results trended favorably toward selpercatinib, though data remain immature at this analysis stage, with limited events recorded to date.
Addressing an Underserved Patient Population
Roughly 85 percent of all lung cancer diagnoses in the United States are classified as NSCLC, with approximately 30 percent of patients presenting with stage IB-IIIA disease. While about half of NSCLC patients harbor actionable biomarkers, RET fusions represent a relatively rare subset, identified in one to two percent of all NSCLC cases. This rarity has historically left many RET fusion-positive patients without targeted treatment options specifically designed for their molecular profile.
LIBRETTO-432 represents the first and only randomized Phase 3 study evaluating a selective RET kinase inhibitor as adjuvant therapy in this patient population, filling a critical gap in early-stage lung cancer treatment.
Trial Design and Patient Enrollment
The global, multicenter, double-blind, placebo-controlled trial enrolled 151 patients who were randomized on a 1:1 basis to receive either selpercatinib or placebo as adjuvant therapy. Participants had completed definitive radiotherapy or surgery with curative intent, along with any indicated additional adjuvant therapy prior to trial enrollment.
The primary analysis focused on the stage II-IIIA subset of patients, with secondary endpoints including overall survival, EFS as assessed by blinded independent central review, time to distant central nervous system disease recurrence, and progression-free survival on subsequent treatment lines. Researchers also evaluated the positive predictive value of various RET testing methodologies from investigator-identified laboratories against Lilly’s designated RET test, as well as safety and tolerability outcomes.
Safety Profile
The overall safety profile of selpercatinib in LIBRETTO-432 was generally consistent with previously reported trials in the broader selpercatinib development program. However, the medication carries several important safety considerations that require careful patient monitoring.
Key adverse events observed in prior trials included hypertension (occurring in 41 percent of patients, with Grade 3 events in 20 percent), which typically responded to antihypertensive medications. Diarrhea affected 47 percent of patients, while fatigue occurred in 46 percent. QT interval prolongation was noted in 21 percent of patients, requiring electrocardiogram monitoring.
More serious but less common adverse reactions included interstitial lung disease (1.8 percent), hepatotoxicity with Grade 3-4 liver enzyme elevations in 11-12 percent of patients, and hemorrhagic events in 22 percent of patients, with fatal hemorrhages occurring in 0.5 percent. Hypersensitivity reactions, including Stevens-Johnson Syndrome, have been reported both in clinical trials and the post-marketing setting.
Given these safety considerations, the FDA-approved prescribing information recommends regular monitoring of liver function tests, blood pressure, QT intervals, and thyroid function. The medication is contraindicated in patients with uncontrolled hypertension and requires dose adjustments in certain patient populations and drug interactions.
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
The LIPFENDRA FDA approval makes Merck's enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 […]
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review […]
Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook
This Johnson & Johnson Q2 2026 Analysis breaks down JNJ's second-quarter results $25.3 billion in worldwide sales, raised full-year guidance, and standout performance from its […]
Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment
The European Commission has approved Merck's Erbitux BRAF V600E mCRC combination regimen cetuximab plus encorafenib and FOLFOX as first-line therapy for metastatic colorectal cancer with […]
Path Forward
Detailed results from LIBRETTO-432 will be presented at an upcoming medical congress, submitted to a peer-reviewed journal, and discussed with health authorities worldwide. The company anticipates these results will inform regulatory discussions regarding potential label expansions and clinical practice guidelines for adjuvant therapy in early-stage RET fusion-positive NSCLC.
The positive outcomes also validate Lilly’s broader RET-targeting strategy, which includes LIBRETTO-431, an ongoing Phase 3 study in advanced NSCLC, and LIBRETTO-001, an earlier pivotal trial that previously demonstrated selpercatinib’s efficacy in advanced RET-altered cancers.
Last Modified:
